Literature DB >> 14742981

Biochemical prognostic markers of outcome in non-paracetamol-induced fulminant hepatic failure.

Konstantinos J Dabos1, Philip N Newsome, John A Parkinson, Hazem H Mohammed, Ian H Sadler, John N Plevris, Peter C Hayes.   

Abstract

BACKGROUND: Fulminant hepatic failure (FHF) is associated with major metabolic disturbances, the onset and severity of which can predict clinical outcome. This study uses admission blood samples to identify early biochemical markers of clinical outcome in patients with non-paracetamol-induced FHF. PATIENTS AND METHODS: Fifty-nine patients admitted to the Scottish Liver Transplant Unit with non-paracetamol-induced FHF were studied. Plasma samples were collected at a median of 5.4 hr after admission to our unit and analyzed using conventional laboratory tests and nuclear magnetic resonance spectroscopy.
RESULTS: A total of 19 patients underwent transplantation, 15 patients died without undergoing transplantation, and 25 patients survived with medical management alone. There were significantly lower levels of lactate, alanine, valine, and bilirubin and significantly higher levels of pyruvate and albumin in patients who survived spontaneously compared with the other two groups. By use of multiple logistic regression analysis, an equation was devised that best predicted clinical outcome: 0.5x(albumin [g/L])-2x(lactate [mmol/L])-36x(valine [mmol/L])-38x(pyruvate [mmol/L]). Values of less than 2 were associated with poor clinical outcome and had a positive predictive value of 91%, a negative predictive value of 86%, a sensitivity of 94%, and a specificity of 86% for death or transplantation. This algorithm can be applied on admission, thus expediting decision-making.
CONCLUSION: We identified biochemical markers that may be useful in predicting outcome in patients with non-paracetamol-induced FHF and should be evaluated further in a different patient population.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14742981     DOI: 10.1097/01.TP.0000100466.22441.37

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  5 in total

1.  (1)H nuclear magnetic resonance spectroscopy-based metabonomic study in patients with cirrhosis and hepatic encephalopathy.

Authors:  Konstantinos John Dabos; John Andrew Parkinson; Ian Howard Sadler; John Nicholas Plevris; Peter Clive Hayes
Journal:  World J Hepatol       Date:  2015-06-28

2.  Impaired gluconeogenesis in a porcine model of paracetamol induced acute liver failure.

Authors:  Konstantinos J Dabos; Henry R Whalen; Philip N Newsome; John A Parkinson; Neil C Henderson; Ian H Sadler; Peter C Hayes; John N Plevris
Journal:  World J Gastroenterol       Date:  2011-03-21       Impact factor: 5.742

3.  Arterial steroid injection therapy can inhibit the progression of severe acute hepatic failure toward fulminant liver failure.

Authors:  Kazuhiro Kotoh; Munechika Enjoji; Makoto Nakamuta; Tsuyoshi Yoshimoto; Motoyuki Kohjima; Shusuke Morizono; Shinsaku Yamashita; Yuki Horikawa; Kengo Yoshimitsu; Tsuyoshi Tajima; Yoshiki Asayama; Kousei Ishigami; Masakazu Hirakawa
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

4.  Non-isotopic tyrosine kinetics using an alanyl-tyrosine dipeptide to assess graft function in liver transplant recipients - a pilot study.

Authors:  Claus G Krenn; Herwig Pokorny; Klaus Hoerauf; Josef Stark; Erich Roth; Heinz Steltzer; Wilfred Druml
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

Review 5.  Prediction of poor outcome in patients with acute liver failure-systematic review of prediction models.

Authors:  Kama A Wlodzimirow; Saeid Eslami; Robert A F M Chamuleau; Martin Nieuwoudt; Ameen Abu-Hanna
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.